Oral IC/BPS Agents
Category: Pharmacology → Bladder Pain & IC/BPS Last reviewed: April 2026
Overview
The 2022 AUA Guideline (Statement 14, Option; Grade B–C) lists four oral agents — amitriptyline, cimetidine, hydroxyzine, pentosan polysulfate (PPS) — as acceptable first-line pharmacotherapy for IC/BPS, arranged alphabetically with no hierarchy implied.[1] Cyclosporine A is an off-label fifth agent with the strongest efficacy signal in comparative trials but a toxicity profile that reserves it for refractory disease. Selection is individualized by phenotype (Hunner vs non-Hunner), comorbidity (pain, sleep, anxiety), and side-effect tolerance.[2][3]
This page covers the oral agents as a pharmacology class. For the broader condition — diagnosis, phenotyping, and the full multimodal algorithm — see IC/BPS.
Mechanism of Action
Five distinct mechanistic classes target different points in the IC/BPS cascade:
| Agent | Class | Principal mechanism |
|---|---|---|
| Amitriptyline | Tricyclic antidepressant | Central analgesia (NE/5-HT reuptake inhibition), antihistamine (H1), anticholinergic (M1), sodium-channel modulation |
| Pentosan polysulfate (PPS) | Semisynthetic GAG analog | Urothelial GAG-layer restoration; reduces urinary-solute permeability |
| Hydroxyzine | H1 antihistamine | Mast-cell stabilization; histamine-H1 receptor blockade |
| Cimetidine | H2 antagonist | Mast-cell / H2 receptor effects; immune modulation (less well characterized) |
| Cyclosporine A | Calcineurin inhibitor | T-cell immunosuppression; particularly active in the B-cell-rich Hunner-lesion phenotype |
Agents in This Class
| Generic Name | Brand / Key Names | Route | Status | Notes |
|---|---|---|---|---|
| Amitriptyline | Elavil (historical) | PO | Off-label | First-line for IC/BPS with pain + sleep disturbance |
| Pentosan polysulfate sodium | Elmiron | PO | FDA-approved for IC (1996) | Only FDA-approved oral agent; maculopathy risk |
| Hydroxyzine | Atarax, Vistaril | PO | Off-label | Helpful when allergic/atopic phenotype |
| Cimetidine | Tagamet | PO | Off-label | Many CYP450 drug interactions |
| Cyclosporine A | Neoral, Sandimmune, Gengraf | PO | Off-label | Best efficacy signal; reserved for refractory disease; nephrotoxic |
Indications in Reconstructive Urology
Primary: chronic bladder/pelvic pain meeting IC/BPS criteria after failure or insufficient response to behavioral and self-care measures.[1]
Phenotype-directed use:
- Hunner-lesion IC/BPS — cyclosporine A has the strongest responder-rate signal and is the oral agent of choice when fulguration/triamcinolone fails or symptoms recur quickly.[3][4]
- Pain-dominant, sleep-disturbed, or comorbid neuropathic-pain presentations — amitriptyline leverages its analgesic + sedating profile.[5]
- Allergic/atopic phenotype (elevated urinary histamine, coexisting dermatologic allergy) — hydroxyzine is the conceptual fit, though controlled evidence is weak.[6]
- Non-Hunner, treatment-naïve — PPS or amitriptyline are typical starting choices, with PPS requiring the maculopathy counseling below.
Dosing & Administration
Doses listed are for reference only. Confirm with current guidelines and institutional protocols. TCA, antihistamine, and immunosuppressant dosing must be individualized to patient comorbidities, concomitant medications, and renal/hepatic function.
| Agent | Starting dose | Titration target | Duration before judging efficacy |
|---|---|---|---|
| Amitriptyline | 10–25 mg PO qhs | 50–75 mg qhs as tolerated | 6–12 weeks |
| Pentosan polysulfate | 100 mg PO TID (on empty stomach, with water) | No titration — continue 3–6 months minimum | 3–6 months (often longer for full effect) |
| Hydroxyzine | 25 mg PO qhs | 50–75 mg qhs | 4–8 weeks |
| Cimetidine | 400 mg PO BID | — | 4–8 weeks |
| Cyclosporine A | 1.5 mg/kg PO BID (3 mg/kg/day total) | Up to 2.5 mg/kg/day split BID with trough monitoring | 3–6 months |
General principles:
- Start low and titrate — particularly for TCA and hydroxyzine where sedation is dose-limiting
- PPS requires baseline retinal exam and periodic follow-up (see maculopathy below)
- Cyclosporine requires baseline and serial BP, renal function (Cr, eGFR), CBC, LFTs, electrolytes (Mg, K), and trough level monitoring
- Amitriptyline at 25 mg qhs is the most tolerated dose; 50 mg often limited by anticholinergic side effects
- Failure of one agent does not predict failure of another — sequential or combination trials are reasonable[1][2]
Contraindications & Precautions
Amitriptyline
- Contraindicated: recent MI, uncorrected QT prolongation, concurrent MAOI use (2-week washout)
- Caution: narrow-angle glaucoma, BPH with retention risk, cardiac conduction disease, serotonergic polypharmacy (serotonin syndrome), elderly (anticholinergic burden, falls)
- Typical side effects: dry mouth, constipation, sedation, weight gain, orthostasis, urinary retention (ironic in this population)
Pentosan polysulfate
- Black-box-adjacent safety alert: progressive, vision-threatening pigmentary maculopathy — dose- and duration-dependent; may progress even after discontinuation.[7][8][9]
- FDA-aligned screening:[1] detailed ophthalmologic history before initiation; baseline retinal exam in patients with preexisting eye conditions; retinal exam within 6 months of starting treatment; periodic retinal exams while on treatment; reassess risk/benefit if pigmentary changes develop.
- Bleeding risk: PPS has weak anticoagulant activity — caution with concurrent anticoagulants, NSAIDs, or bleeding disorders.
- Hepatic dysfunction reported; check LFTs periodically.
Hydroxyzine
- Contraindicated: early pregnancy, known QT prolongation (dose-dependent QTc effect)
- Caution: elderly (sedation, anticholinergic burden), concurrent CNS depressants
Cimetidine
- Significant CYP450 inhibition — major drug-interaction profile (warfarin, phenytoin, theophylline, TCAs, benzodiazepines, β-blockers, opioids). Review the full medication list before prescribing.
- Caution: elderly (confusion), renal impairment (dose reduction), concurrent antiarrhythmics
Cyclosporine A
- Contraindicated: uncontrolled hypertension, renal impairment, active infection, malignancy (relative)
- Monitoring-dependent: BP at every visit; Cr/eGFR every 2–4 weeks initially then quarterly; LFTs, CBC, electrolytes; trough levels 100–200 ng/mL
- Major drug interactions via CYP3A4 (statins — rhabdomyolysis; macrolides; azoles; grapefruit juice)
- Long-term risks: nephrotoxicity, hypertension, gingival hyperplasia, hypertrichosis, increased infection and malignancy risk
Perioperative Considerations
| Agent | Periop action | Rationale |
|---|---|---|
| Amitriptyline | Generally continue; document for anesthesia | Anticholinergic burden, QT, orthostasis — coordinate with anesthesia if prolonged operation or cardiac comorbidity |
| PPS | Hold 7 days before major surgery (bleeding-risk cases) | Weak anticoagulant activity |
| Hydroxyzine | Continue; often held day-of for PONV drugs | Additive sedation with anesthetics |
| Cimetidine | Continue; flag CYP450 interactions to pharmacy | Can alter anesthetic drug levels |
| Cyclosporine A | Discuss with transplant/rheum prescribing colleague | Perioperative infection risk; wound healing; nephrotoxicity under hemodynamic stress — do not hold without discussion given flare risk |
Evidence Summary
| Agent | Evidence | Key reference |
|---|---|---|
| PPS | Largest long-term cohort; FDA-approved. Mixed efficacy in RCTs; Cochrane network MA shows modest benefit. Confirmed maculopathy risk. | Sant 2003 ICCTG[6]; Hall 2025[7] |
| Amitriptyline | NIH-sponsored RCT (Foster 2010) — benefit confined to patients reaching effective dose (50 mg); network MA shows significant ICSI reduction (MD −4.9) | Foster 2010[5]; Di 2021[3] |
| Hydroxyzine | Sant 2003 ICCTG RCT — hydroxyzine alone or with PPS did not show significant benefit over placebo. Commonly used on expert-opinion basis. | Sant 2003[6] |
| Cimetidine | Small RCT (Thilagarajah 2001, n=34) — pain and symptom improvement vs placebo. Limited subsequent validation. | Thilagarajah 2001[10] |
| Cyclosporine A | Sairanen 2005 RCT vs PPS — responder rate 75% vs 19% (p<0.001). Bayesian network MA ranks it top for ICSI, ICPI, and VAS. Particularly effective for Hunner phenotype. | Sairanen 2005[4]; Di 2021[3] |
| Cochrane overview | Network MA of 81 RCTs confirms small-to-moderate benefits with significant heterogeneity across agents. | Imamura 2020[11] |
Practical Pearls
- Amitriptyline dosing — 10 mg qhs for 1 week then 25 mg for 2–4 weeks before judging. Titrate to 50–75 mg only if tolerating. The Foster RCT's negative primary result reflects intention-to-treat including non-tolerators; per-protocol analysis at effective doses is more favorable.[5]
- PPS counseling is non-negotiable — the maculopathy conversation (and documentation of it) must happen before the first prescription. Schedule baseline ophthalmology before you send the script. Some patients will decline PPS on this basis — that is a reasonable choice.[7][8]
- Cimetidine before famotidine — for this indication specifically; the IC/BPS literature is with cimetidine, not substituted H2 blockers. The trade-off is cimetidine's drug-interaction profile.
- Cyclosporine needs a team — don't start it without a rheumatologist, transplant nephrologist, or IC-experienced colleague to help with monitoring and dose adjustment. Failure to monitor is how patients lose kidney function.[4]
- Stop criteria — 6–8 weeks of adequate dose with no benefit is a reasonable trigger to transition. Longer PPS trials (3–6 months) are justified given its slow mechanism.
- Sequential trials are normal — patients may cycle through 2–3 agents before finding one that helps. Document why each was chosen and why each was discontinued.
- Combination therapy is common in practice even without strong trial support — e.g., amitriptyline + PPS, or amitriptyline + hydroxyzine for overlapping sleep/allergy symptoms.[1][2]
Related Articles
- IC/BPS — full condition article
- Intravesical IC/BPS Agents — DMSO, lidocaine, heparin, HA, chondroitin
- Assessment Tools & Questionnaires — ICSI, ICPI, GUPI, VAS for response measurement
References
1. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome." J Urol. 2022;208(1):34-42. doi:10.1097/JU.0000000000002756
2. Chermansky CJ, Guirguis MO. "Pharmacologic Management of Interstitial Cystitis/Bladder Pain Syndrome." Urol Clin North Am. 2022;49(2):273-282. doi:10.1016/j.ucl.2022.01.003
3. Di XP, Luo DY, Jin X, et al. "Efficacy and Safety Comparison of Pharmacotherapies for Interstitial Cystitis and Bladder Pain Syndrome: A Systematic Review and Bayesian Network Meta-Analysis." Int Urogynecol J. 2021;32(5):1129-1141. doi:10.1007/s00192-020-04659-w
4. Sairanen J, Tammela TL, Leppilahti M, et al. "Cyclosporine A and Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis: A Randomized Comparative Study." J Urol. 2005;174(6):2235-8. doi:10.1097/01.ju.0000181808.45786.84
5. Foster HE Jr, Hanno PM, Nickel JC, et al. "Effect of Amitriptyline on Symptoms in Treatment Naïve Patients With Interstitial Cystitis/Painful Bladder Syndrome." J Urol. 2010;183(5):1853-8. doi:10.1016/j.juro.2009.12.106
6. Sant GR, Propert KJ, Hanno PM, et al. "A Pilot Clinical Trial of Oral Pentosan Polysulfate and Oral Hydroxyzine in Patients With Interstitial Cystitis." J Urol. 2003;170(3):810-815. doi:10.1097/01.ju.0000083020.06212.3d
7. Hall BP, Shiromani S, Vanderbeek BL, et al. "Pentosan Polysulfate Maculopathy: Clinical Considerations, Pathobiology, and Causality." Prog Retin Eye Res. 2025:101400. doi:10.1016/j.preteyeres.2025.101400
8. McGwin G, MacLennan P, Owsley C. "Association Between Pentosan Polysulfate Sodium and Retinal Disorders." JAMA Ophthalmol. 2022;140(1):37-42. doi:10.1001/jamaophthalmol.2021.4778
9. Lindeke-Myers A, Hanif AM, Jain N. "Pentosan Polysulfate Maculopathy." Surv Ophthalmol. 2022;67(1):83-96. doi:10.1016/j.survophthal.2021.05.005
10. Thilagarajah R, Witherow RO, Walker MM. "Oral Cimetidine Gives Effective Symptom Relief in Painful Bladder Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial." BJU Int. 2001;87(3):207-12. doi:10.1046/j.1464-410x.2001.02031.x
11. Imamura M, Scott NW, Wallace SA, et al. "Interventions for Treating People With Symptoms of Bladder Pain Syndrome: A Network Meta-Analysis." Cochrane Database Syst Rev. 2020;7:CD013325. doi:10.1002/14651858.CD013325.pub2